Axon Enterprise, Inc. (NASDAQ:AXON) Shares Bought by Chicago Capital LLC

Chicago Capital LLC grew its holdings in shares of Axon Enterprise, Inc. (NASDAQ:AXON) by 0.2% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 21,583 shares of the biotechnology company’s stock after buying an additional 45 shares during the quarter. Chicago Capital LLC’s holdings in Axon Enterprise were worth $8,625,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. Commonwealth Equity Services LLC boosted its stake in Axon Enterprise by 7.5% during the 3rd quarter. Commonwealth Equity Services LLC now owns 75,201 shares of the biotechnology company’s stock valued at $30,050,000 after acquiring an additional 5,218 shares during the last quarter. Friedenthal Financial acquired a new stake in shares of Axon Enterprise in the 3rd quarter valued at about $51,000. Blue Trust Inc. lifted its position in shares of Axon Enterprise by 234.5% during the third quarter. Blue Trust Inc. now owns 291 shares of the biotechnology company’s stock worth $116,000 after purchasing an additional 204 shares during the last quarter. Stratos Wealth Advisors LLC acquired a new position in Axon Enterprise in the third quarter worth about $259,000. Finally, CHB Investment Group LLC bought a new stake in Axon Enterprise in the third quarter valued at about $3,626,000. Institutional investors and hedge funds own 79.08% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have commented on the company. Robert W. Baird increased their target price on Axon Enterprise from $360.00 to $400.00 and gave the stock an “outperform” rating in a report on Tuesday, September 10th. Barclays raised their price objective on Axon Enterprise from $381.00 to $387.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 7th. Jefferies Financial Group initiated coverage on shares of Axon Enterprise in a research note on Wednesday, July 17th. They set a “buy” rating and a $385.00 target price for the company. Craig Hallum increased their target price on shares of Axon Enterprise from $370.00 to $376.00 and gave the stock a “buy” rating in a report on Wednesday, August 7th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $400.00 price target on shares of Axon Enterprise in a report on Wednesday, August 7th. Two equities research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $365.38.

Axon Enterprise Stock Performance

Shares of NASDAQ AXON opened at $438.05 on Friday. Axon Enterprise, Inc. has a 12-month low of $199.29 and a 12-month high of $440.89. The company has a current ratio of 2.88, a quick ratio of 2.52 and a debt-to-equity ratio of 0.35. The company has a market cap of $33.10 billion, a PE ratio of 115.58, a P/E/G ratio of 11.74 and a beta of 0.94. The stock has a 50 day simple moving average of $388.71 and a 200-day simple moving average of $331.79.

Axon Enterprise (NASDAQ:AXON) last announced its quarterly earnings results on Tuesday, August 6th. The biotechnology company reported $1.20 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.02 by $0.18. The company had revenue of $504.00 million during the quarter, compared to analyst estimates of $478.35 million. Axon Enterprise had a return on equity of 9.34% and a net margin of 16.06%. The firm’s quarterly revenue was up 34.5% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.80 EPS. On average, equities research analysts forecast that Axon Enterprise, Inc. will post 1.79 EPS for the current year.

Insider Activity at Axon Enterprise

In other Axon Enterprise news, Director Julie A. Cullivan sold 900 shares of the business’s stock in a transaction dated Thursday, September 5th. The shares were sold at an average price of $353.53, for a total transaction of $318,177.00. Following the sale, the director now directly owns 3,653 shares in the company, valued at approximately $1,291,445.09. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In other news, Director Julie A. Cullivan sold 900 shares of Axon Enterprise stock in a transaction on Thursday, September 5th. The stock was sold at an average price of $353.53, for a total transaction of $318,177.00. Following the transaction, the director now directly owns 3,653 shares in the company, valued at approximately $1,291,445.09. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Michael Garnreiter sold 1,000 shares of the company’s stock in a transaction on Tuesday, October 15th. The shares were sold at an average price of $437.98, for a total value of $437,980.00. Following the completion of the sale, the director now owns 26,259 shares of the company’s stock, valued at approximately $11,500,916.82. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 371,172 shares of company stock worth $137,000,162 in the last 90 days. Corporate insiders own 5.70% of the company’s stock.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.